Coherus Oncology, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
CHRS$0.64-21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended | ||||||
| · · March 31, | ||||||
| · · 2026 · · 2025 | ||||||
| Net revenue | | $12,310 | | $7,599 | ||
| Costs and expenses: | | | | | ||
| Cost of goods sold | | 3,814 | | 2,653 | ||
| Research and development | | 21,543 | | 24,356 | ||
| Selling, general and administrative | | 23,104 | | 26,025 | ||
| Total costs and expenses | | 48,461 | | 53,034 | ||
| Loss from operations | | (36,151) | | (45,435) | ||
| Interest expense | | (2,186) | | (2,150) | ||
| Other income (expense), net | | 1,402 | | 187 | ||
| Loss from continuing operations before income taxes | | (36,935) | | (47,398) | ||
| Income tax provision | | — | | — | ||
| Net loss from continuing operations | | | (36,935) | | | (47,398) |
| Net loss from discontinued operations, net of tax (Note 6) | | | (1,392) | | | (9,171) |
| Net loss | | $(38,327) | | $(56,569) | ||
| | | | | | | |
| Net loss per share from continuing operations - basic and diluted | | $(0.27) | | $(0.41) | ||
| Net loss per share from discontinued operations - basic and diluted | | $(0.01) | | $(0.08) | ||
| Net loss per share - basic and diluted | | $(0.28) | | $(0.49) | ||
| | | | | | | |
| Weighted-average number of shares used in computing net loss per share: | | | | | | |
| Basic and diluted | | | 136,398,303 | | | 115,857,780 |
| | | | | | | |
| Comprehensive loss: | | | | | | |
| Net loss | | $(38,327) | | $(56,569) | ||
| Other comprehensive loss: | | | | | | |
| Unrealized loss on available-for-sale securities, net of tax | | | (73) | | | — |
| Comprehensive loss | | $(38,400) | | $(56,569) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.